Affimed (AFMD) Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Addition of Affimed’s innate cell engager improves cytotoxicity of natural killer cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells with.
Message :
Required fields AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15. In addition, early data from a Phase 1 study evaluating AFM13 preloaded
E-Mail
Members of the German Bundestag who belong to underrepresented groups are more active in the legislative process and, early on, typically tend to advocate more for the interests of their groups. However, a current study by the universities in Konstanz, Basel, Geneva and Stuttgart indicates that, after a few years, most of them do move on to other political fields. This is tied to the career-related incentives these elected representatives face: At first, their careers in parliament benefit from their ability to speak for underrepresented groups. As their careers progress, however, they are required to demonstrate expertise in areas beyond the interests of these groups, the researchers conclude.